In paragraph 1, the first paragraph of paragraph 1 shall be replaced by the second paragraph of paragraph 1, which shall be replaced by the second paragraph of paragraph 1, by the second paragraph of paragraph 1, by the second paragraph of paragraph 1, by the second paragraph of Article 1. This law shall govern a matter referred to in Article 74 of the Constitution. TITLE 2. - Health CHAPTER 1. - Amendments to the law on compulsory medical care insurance and benefits, coordinated on 14 July 1994 Section 1. - Extension of the procedure for off-patent versions of complex medicinal products and deepening the price reduction in the case of the reference refund Art. 2. In Article 35b of the law on compulsory medical care and benefits, coordinated on 14 July 1994, inserted by the law of 2 January 2001 and last amended by the law of 20 December 2020, the following amendments shall be made to paragraph 1, the third and fourth paragraph shall be replaced by the former paragraph 1, which shall be replaced by the following: "The provisions of paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1 shall be replaced by the following:in paragraph 1, the words "paragraphs 1 or 2a" shall be replaced by the words "paragraphs 1 and 2a" in paragraphs 1 and 5; the words "paragraphs 1 and 2a" shall be replaced by the words "paragraphs 1 and 2a"; the words "paragraphs 1 and 2a" shall be replaced by the words "paragraphs 1 and 2a" shall be replaced by the words "paragraphs 1 and 2a" before 1 September 2021; the words "paragraphs 1 and 2a" shall be replaced by the words "paragraphs 1 and 2a."Article 73 of the same law, as last amended by the Act of 20 December 2020, shall be amended as follows:The first paragraph of paragraph 2 shall be replaced by the second paragraph of paragraph 2; the second paragraph of paragraph 2 shall be replaced by the fourth paragraph of paragraph 2; the second paragraph of paragraph 2 shall be replaced by the fourth paragraph of paragraph 2; the second paragraph of paragraph 2 shall be replaced by the fourth paragraph of paragraph 2; the second paragraph of paragraph 2 shall be replaced by the fourth paragraph of paragraph 2; the second paragraph of paragraph 2 shall be replaced by the fourth paragraph of paragraph 2; the third paragraph of paragraph 2 shall be replaced by the fourth paragraph of paragraph 1 shall be replaced by the fourth paragraph of paragraph 2; the fourth paragraph of paragraph 1 shall be replaced by the fourth paragraph of paragraph 2;in paragraph 1, the first paragraph shall be replaced by the following: "second paragraph, paragraph 1 shall be replaced by the following: "second paragraph, paragraph 1 shall be replaced by the following: "second paragraph, paragraph 1 shall be replaced by the following: "second paragraph, paragraph 1 shall be replaced by the following: "second paragraph, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 2 shall be replaced by the following: "second paragraph, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 2 shall be replaced by the following: "second paragraph, paragraph 1, paragraph 1, paragraph 1, paragraph 2 shall be replaced by the following: "second paragraph, paragraph 1, paragraph 1, paragraph 2 shall be replaced by the following: "second paragraph, paragraph 1, paragraph 2 shall be replaced by the following: "second paragraph, paragraph 1, paragraph 1, paragraph 1, paragraph 2 shall be replaced by the following: "second paragraph, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1 shall be replaced by the following: "second paragraph, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1, paragraph 1 shall be replaced by the following:in paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 5, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, paragraph 2, the first, paragraph 2, the first, paragraph 2, the second, paragraph 2, the first, paragraph 2, the first, paragraph 2, the first, paragraph 2, the second, paragraph 2, the second, paragraph 2, the second, paragraph 2, the second, the second, the first, the first, the first, the first, the first, the first, the second, the second, the second, the first, the second, the second, the second, the second, the second, the second, the second, the second, the second, the second, the second, the second, the second, the second, the second, the second, the second, the second, the second, the second, the second, the second, theArticle 69 of the Law of 27 April 2005 on the control of the health budget, as last amended by the Law of 20 December 2020, shall be replaced by the words "the fifth and thirteenth paragraphs', by the words "the sixth paragraph', by the words "the sixth paragraph', by the words "the sixth paragraph', by the words "the sixth paragraph', by the words "the sixth paragraph', by the words "the sixth paragraph', by the phrase "the sixth paragraph', by the words "the sixth paragraph', by the phrase "the ninth paragraph', by the words "the sixth paragraph', by the words "the fourth paragraph and by the ninth paragraph'.In 2020, - 28,27 % if the active substance concerned (or the combination of active substances) generated a corrected annual turnover equal to or more than EUR 30 million and less than EUR 40 million in 2020, - 29,69 % if the active substance (or combination of active substances) concerned has generated a corrected annual turnover equal to or more than EUR 50 million and less than EUR 60 million in 2020, - 32,54 % if the active substance (or combination of active substances) concerned has generated a corrected annual turnover equal to or more than EUR 60 million and less than EUR 70 million in 2020, - 33,97 % if the active substance (or combination of active substances) concerned has generated a corrected annual turnover equal to or more than EUR 70 million in 2020, with the exception of the specialities included in the remuneration group VII.9, in so far as the provisions of this article have not been applied to these specialties on 1 January 2022, and in respect of the annual remuneration referred to in Article 34, the first subparagraph of the first subparagraph of Article 34, the first subparagraph of Article 34 of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the second subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the second subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the first subparagraph of the second subparagraph of the first subparagraph of the second subparagraph of the second subparagraph of the first subparagraph of the first subparagraph of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article- 28,27 % if the active substance (or combination of active ingredients) concerned has a corrected annual turnover equal to or more than EUR 40 million and less than EUR 50 million in the year "t-2', - 31,12 % if the active component (or combination of active components) concerned has a corrected annual turnover equal to or more than EUR 50 million and less than EUR 60 million in the year "t-2', - 32,54 % if the active component (or combination of active components) concerned has generated a corrected annual turnover equal to or less than EUR 60 million and if the active component (or combination of active components) in the year "t-2', - 32,54 % if the active component (or combination of active ingredients) concerned has generated a corrected annual turnover equal to or more than EUR 60 million and less than EUR 70 million in the year "t-2', - 33,97 % if the active component concerned has generated an annual turnover equal to or less than EUR 33,97 % if the active component (or combination of active components) in the year "t-2' has generated an annual turnover equal to or less than EUR 50 million and less than EUR 60 million in the year "t-2', or the annual turnover equal to or more than EUR 50 million in the year "t-2'.(or the combination of active ingredients) a corrected annual turnover equal to or more than EUR 10 million and has generated less than EUR 20 million in the year "t-1', - 26,85 % if the active substance (or combination of active components) concerned has generated a corrected annual turnover equal to or more than EUR 30 million and less than EUR 40 million in the year "t-1', - 29,69 % if the active component (or combination of active components) has generated a corrected annual turnover equal to or more than EUR 40 million and has generated less than EUR 50 million in the year "t-1', - 31,12 % if the active component (or combination of active components) concerned has a corrected annual turnover equal to or more than EUR 50 million and less than EUR 60 million in the year "t-1', if the active component (or combination of active components) has generated less than EUR 32,54 % if the active component concerned in the year "t-1' and less than EUR 50 million in the year "or combination of active components',The same law, a new price and basis of remuneration shall be established, with the exception of the specialities included in the fee group VII.9 and with the exception of the specialties covered by Article 35ter, § 1a or § 2 of the same law, reduced in accordance with the provisions of paragraph 1 to the extent that the provisions of this Article have not yet been applied to those specialties. On 1 October 2021 and thereafter on 1 January 2001, on 1 April and on 1 July and on 1 October, the prices and reimbursement bases of the biological medicinal products, as defined by the Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 laying down a Community code on medicinal products for human use, for which a new price and reimbursement basis is established, shall also be reduced, in accordance with the provisions of Article 30 (1) of the Law of 30 July 2013, on 1 September 2021, on the prices and reimbursement bases of the specialties referred to in Article 34, first paragraph 5 (c), 1 of the law on compulsory medical care and benefits, coordinated on 14 July 1994, in accordance with the provisions of Article 1, point 1, point 1, point 1 of Article 1 of Article 1 of Article 1 of Article 3 of Article 3 of the basic Regulation.In 2020, - 29,69 % if the active substance (or combination of active ingredients) concerned has generated a corrected annual turnover equal to or more than EUR 50 million and less than EUR 60 million in 2020, - 32,54 % if the active ingredient (or combination of active components) concerned has generated an adjusted annual turnover equal to or more than EUR 60 million and less than EUR 70 million in 2020, - 33,97 % if the active ingredient (or combination of active ingredients) concerned has generated an annual turnover equal to or more than EUR 70 million in 2020. On 1 September 2021, the prices and remunerations of the specialities referred to in Article 34, first paragraph 5°, (c), 1), of the law on compulsory medical care and benefits, coordinated on 14 July 1994, entered in Chapters I, II, IV and VIII of the list of the pharmaceutical sectors referred to in Article 1, paragraph 1, shall be calculated in accordance with the following:Chapter III of the abovementioned list, reduced by: - 19,75 % if the active substance (or combination of active substances) concerned has generated a corrected annual turnover equal to or more than EUR 1,5 million and less than EUR 10 million in 2020, - 26,15% if the active substance (or combination of active substances) concerned has generated a corrected annual turnover equal to or more than EUR 10 million and less than EUR 20 million in 2020, - 26,85 % if the active substance (or combination of active substances) concerned has generated a corrected annual turnover equal to or more than EUR 20 million and less than EUR 30 million in 2020, - 28,27 % if the active substance (or combination of active substances) in question has generated a corrected annual turnover equal to or less than EUR 30 million and less than EUR 40 million in 2020, - 29,69 % if the active ingredient (or combination of active components) concerned has generated an annual turnover equal to or less than EUR 30 million in 2020, or less than EUR 40 million in 2020, - 28,27 % if the active component (or combination of active ingredients) concerned has generated a corrected annual turnover equal to or less than EUR 50 million in 2020, or less than EUR 50 million in 2020, or less than EUR 50 million in 2020, or less than its annual turnover equal to or less than EUR 50 million in 2020,- 40,35 % if the active substance (or combination of active ingredients) in question has generated a corrected annual turnover equal to or more than EUR 1,5 million and less than EUR 10 million in 2020, - 40,92 % if the active substance (or combination of active components) in question has generated a corrected annual turnover equal to or more than EUR 10 million and less than EUR 20 million in 2020, - 41,48 % if the active substance (or combination of active ingredients) in question has generated a corrected annual turnover equal to or less than EUR 20 million in 2020, - 41,48 % if the active substance (or combination of active ingredients) in question has generated a corrected annual turnover equal to or less than EUR 20 million and less than EUR 30 million in 2020, - 42,62 % if the active ingredient (or combination of active ingredients) in question has generated an annual turnover equal to or less than EUR 50 million in 2020, - 42,62 % if the active ingredient (or combination of active ingredients) in question has generated an annual turnover equal to or less than EUR 20 million in 2020, or less than EUR 40 million in 2020, or less than EUR 40 million in 2020, or less than EUR 43,For the purposes of Article 35a (1) of the same law, and for the purposes of applying Article 34 (1) of the Code on Medicinal Products for Human Use: 1° of which the applicant has demonstrated that the price and the level of remuneration (out of business), calculated per unit, per component of the active substance (or combination of the active substance) is coordinated on 14 July 1994, in accordance with Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 establishing a Community code on medicinal products for human use, in accordance with the first subparagraph of the first subparagraph of Article 35a (1) of the same law, and in accordance with the second subparagraph of Article 6 (1) of the first subparagraph of the first subparagraph of Article 6 (1) of the basic Regulation on medicinal products for human use, in accordance with the first subparagraph of the first subparagraph of Article 7 (1) of the first subparagraph of the first subparagraph of Article 7 (1) of the first subparagraph of the first subparagraph of Article 7 (1) of the first subparagraph of the first subparagraph of the first subparagraph of Article 35a (1) of the second subparagraph of the second subparagraph of the second subparagraph of Article 7 of the first subparagraph of the second subparagraph of Article 7 of the first subparagraph of the second subparagraph of Article 7 of the first subparagraph of the second subparagraph of Article 7 of the second subparagraph of the first subparagraph of the first subparagraph of Article 1 of the second subparagraph of the first subparagraph of the second subparagraph of Article 1 of the second subparagraph of the first subparagraph of the second subparagraph of the second subparagraph of the second subparagraph of the second subparagraph of the first subparagraph of the second subparagraph of the second subparagraph of the second subparagraph of Article of the second subparagraph of Article of Article of the second subparagraph of Article of Article of Article of Article of Article of the second subparagraph of the second subparagraph of the second subparagraph of the second subparagraph of Article of the second subparagraph of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of the second paragraph of Article of Article of Article of Article of Article of Article of Article 2 of Article of Article of Article of Article 1 of Article 3 of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article 3 of Article of Article of Article of Article 3 of Article of Article of Article 3 of Article 3 of Article 3 of Article of Article 1 of Article 1 of Article of Article of Article of Article of Article of Article of Article of ArticleThe provisions of paragraph 3, first and third paragraphs, may not be applied to the same speciality. § 8. For the specialties referred to in the third paragraph, applicants may choose, on 1 September 2021, to automatically and without taking into account the procedures laid down in Article 35a of the Law on compulsory medical care insurance and benefits, coordinated on 14 July 1994, to remove from the list of recoverable specialities. § 9. The King may amend the percentages referred to in paragraphs 1 to 8; the detailed rules for making known the reduction rates in function of the annual turnover of an active ingredient (or combination of active ingredients) shall be determined by the King. The King may determine an exception for the scope of application of this Article for the proprietary medicinal products to which the applicant has indicated that it or the active ingredients, as included in the Anatomical Therapeutic Chemical Classification of Chemical Classification, shall be determined by the World Health Organisations Collaborating Center for Drug Statistics, which shall be protected by a patent or a certificate in addition to the patent, unless one or more of the essential ingredients of the active substances, as defined by the principle of the principle of the principle of the principle of the principle of principle of principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle of the principle.On 1 April and 1 October of each year, with the exception of the provisions of the Law of 30 December 2013 on Organic Medicinal Products Art. 8. Article 30 of the Law of 30 July 2013 laying down various provisions concerning medicinal products, last amended by the Law of 20 December 2020, shall be replaced as follows: "Art. 30. § 1.The first paragraph of Article 1 of the Law of 25 March 1964 on medicinal products containing the same active substance or active ingredients shall, on 1 November, 1 February, 1 May or 1 August preceding it, be entered in the abovementioned list and not available within the meaning of Article 72a, Paragraph 1a, of the Law on compulsory medical care and benefits, coordinated on 14 July 1994, and the prices and reimbursement bases of the proprietary medicinal products granted in accordance with Article 6a, Paragraph 1, eighth paragraph, of the Law of 25 March 1964 on medicinal products containing the same active substance or active ingredients, shall be reduced by 20% on 1 October 2021 and thereafter on 1 January each year, on 1 July and on 1 October of the Law of 25 March 1964 on the prices and reimbursement bases of the biological medicinal products, as defined by Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 establishing a Community code of medicinal products for human use and veterinary medicinal products, as defined in accordance with Article 6a, paragraph 8 of the Law of the Act of 25 March 1964 on the same active substance and on the same conditions of the principle, and on the basis of the second subparagraph of Article 1 of the second subparagraph of Article 1 of Article 1 of the Law of that Law of that Law of that Law of that Law,If, within a period of 24 months from the adoption of the new price and remuneration basis on the basis of paragraph 2, it appears to the Commission, on the basis of paragraph 2, that there is no more, on the list referred to above, than the same medicinal product authorised in accordance with Article 6a, Paragraph 1, eighth paragraph, of the Law of 25 March 1964 on medicinal products, containing the same active substance or active ingredients, which satisfies the criteria for applying paragraph 2, the basis of consideration and the selling price to the public shall be automatically reduced to an amount equal to the original basis of remuneration and selling price to the public, as applicable before the application of the provisions of paragraph 2;on the basis of Article 6a (1) of the Law of 25 March 1964 on medicinal products containing the same active substance or active ingredients shall give rise to the application of paragraph 2 if a biological medicinal product, granted in accordance with paragraph 1 of Article 6a (1) of the Law of 25 March 1964 on medicinal products containing the same active ingredient or active ingredients, which should give rise to the application of paragraph 2 within the meaning of Article 72a (1) (a) of the Law of 25 March 1964 on compulsory medical care and benefits, coordinated on 14 July 1994, after its registration on the list of the recoverable proprietary medicinal products referred to in Article 35a (1) of the same Law, is notified to that effect less than 20 days before the entry into force of the new price and reimbursement basis in application of paragraph 2, the provisions of paragraph 4, first paragraph 1° and 2° shall apply, or to the first adaptation of the abovementioned list following the expiry of the medicinal product in question, either until the date of another pharmaceutical product, or at the date of entry into force of Article 6a (1) of the Act of the Law of 25 March 1964 on the same date of application to the same date of the same substance or to the same date of application of the same substance, to the first paragraph 2, to the same date of the first paragraph of Article 6, to the first paragraph of the first paragraph of the first paragraph of the first paragraph of Article 6, to the first paragraph of the first paragraph of the first paragraph of the first paragraph of the first subparagraph of the first paragraph of the first paragraph of Article 6, to the first paragraph of the first paragraph of the first paragraph of the first paragraph of the first paragraph of Article of Article of the first paragraph of Article of the first paragraph of Article of Article of the first paragraph of the first paragraph of Article of Article of Article of Article of Article of the first paragraph of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article 1 of Article 1 and of Article 1 and of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article of Article 1 of Article of Article of Article 1 of Article 1 of Article 1 of Article 1 of Article 1 of Article 1 of Article 1 of Article 1 of Article 1 of Article 1 of Article 1 of Article of Article of Article 1 of ArticleFor the same active substance or the same active ingredients, the following shall be applied to the financial year of application of paragraph 2.' TITLE 3. - Social affairs ENIG CHAPTER. - Financing of social security Section 1. - Increase of the overall national allowance to the RSZ-Global Management Art. 9. In Article 21/1 of the Law of 18 April 2017 reforming the financing of social security, inserted by the Law of 21 December 2018, the following amendments shall be made: 1° the words "for the years 2018, 2019 and 2020' shall be replaced by the words "for the years 2018, 2019, 2020 and 2021'; 2° the article shall be supplemented by a paragraph: "From 2022 onwards, the Council of Ministers shall provide for the financing of the medical care Art. 10.Article 12 Article 6 of the Royal Decree of 18 November 1996 introducing a global financial management into the social status of selfemployed persons, pursuant to Chapter I of Title VI of the Law of 26 July 1996 on the modernisation of social security and safeguarding the viability of statutory pension schemes, as last amended by Law 18 April 2017, the following amendments shall be added: 1° in paragraph 1a shall be inserted between the twentieth and the twenty-first paragraphs of a paragraph, stating: "For the financial year 2021 the amount shall be obtained in application of the preceding paragraphs shall be reduced by EUR 36 202 thousand.in paragraph 3, paragraph 1, the words "as well as the administrative supplement referred to in paragraph 1, second paragraph," shall be inserted between the words "assigned sum" and the words "assigned fine"; in paragraph 5, second paragraph, the words "as well as the administrative supplement referred to in paragraph 1, second paragraph," shall be inserted between the words "assigned sum" and the words "assigned" in Article 65 (1) of the same law; in paragraph 5, second paragraph, the words "assignment of the administrative supplement referred to in paragraph 1, second paragraph" shall be inserted between the words "assigned sum" and the words "assignance" in Article 65 (1) of the same law shall be replaced by the words "assignment of the administrative surcharge referred to in paragraph 1, second paragraph, second paragraph, "assignance" and "assignance."In Article 194 of the same Code, and amended by the Act of 21 April 2007, the words "Article 162ter" shall be inserted between the words "Article 162ter" and the words "Article 162ter" shall be inserted in the words "Article 162ter" and the words "Article 162ter" shall be inserted in the words "Article 162ter" and "Article 162ter."in criminal matters between the Member States of the European Union Art. 22. In the Law of 5 August 2006 on the application of the principle of mutual recognition of judicial decisions in criminal matters between the Member States of the European Union, an Article 23/1 shall be inserted: "Art. 23/1. In addition to the sum of money provided for in the certificate, an administrative supplement, as provided for in Title 4 of the Programme Law of 21 June 2021, of 25.32 euro. The amount of this administrative supplement shall be automatically adjusted on 1 January each year in the light of the evolution of the consumption price index of the month of November of the previous year." Section 4. - Amendment of the Law of 1 August 1985 on fiscal and other provisions Art. 23. In Article 29, fourth paragraph, of the Law of 1 August 1985 on fiscal and other provisions, replaced by the Law of 22 April 2003 and last amended by the Law of 19 March 2017, the words "the administrative surcharge referred to in Title 4 of the Programme Act of 21 June 2021" shall be inserted between the words "the second-term support fund" and the words "the second-term financial penalty" shall be replaced by the words "the second-term penalty provided for in Article 5.The words "of the Fund" shall be replaced by the words "of this Part I fund" and "of the Fund" shall be replaced by the words "of the Fund" shall be replaced by the words "of the Fund" shall be replaced by the words "of this Part I fund"; the article shall be supplemented by a paragraph: "in the first paragraph, the amount of EUR 125 000 000 shall be linked to a value of 107,24 corresponding to the average annual value of the consumer price index (base 2013) for the year 2018. This amount shall be indexed each year to follow the evolution of the average annual consumer price index between 2018 and the last year preceding the year in which the purchase takes place." TITLE 6. - Internal Security (ISF) - Programme 2021-2027 Art. 26. A fund for the European Programme 2021-2027 shall be established within the meaning of Article 62 of the Law of 22 May 2003 on the organisation of the budget and the composition of the Federal State.29. Article 37/2, § 4 of the same Act, inserted by the Act of 9 January 2014 and amended by the Act of 29 May 2015, is supplemented by a paragraph, which states: "By way of derogation from Article 26, § 7, paragraph 1, for the recognised organisations pursuant to Article 26, § 3, whose programme has been drawn up according to the academic calendar, their recognition will be renewed by 8 months in 2027." Announcing this Act, recommend that it be held with the Land's seal and will be published by the Belgian Official Journal. Published in Brussels, June 21, 2021. FILIP Van Koningswege : The Prime Minister, A. DE CROO The Minister of Social Affairs and Public Health, Fr. VANDENBROUCKE The Minister of Justice, V. VAN QUICKENBORNE The Minister in charge of Beliris, K. LALIEUX De Minister of Interior Affairs, A. VERLINDE The Minister of Development Co-operation, M. KITIR With's Sealed: The Minister of Justice, V. VAN QUICKENBORNE _____ No (1) Kamer van Beliris, K. LALIEUX De Minister of Interior, A.